CORT - Corcept Therapeutics Incorporated

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Corcept Therapeutics Incorporated

149 Commonwealth Drive
Menlo Park, CA 94025
United States
650-327-3270
http://www.corcept.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees103

Key Executives

NameTitlePayExercisedAge
Dr. Joseph K. Belanoff M.D.1.01M7.14M60
Mr. Gary Charles Robb520.68kN/A54
Dr. Robert S. Fishman M.D., ‚ F.C.C.P.451.36kN/A55
Dr. Hazel Hunt Ph.D.N/AN/AN/A
Donald E. LaferleN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with Cushing’s syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Corporate Governance

Corcept Therapeutics Incorporated’s ISS Governance QualityScore as of October 15, 2017 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.